Financial Research
– Teva sees $3 billion in potential sales by 2020 from 50 new therapeutic entities. – Dr. Michael Hayden – 50 new products with...
Hi, what are you looking for?
– Teva sees $3 billion in potential sales by 2020 from 50 new therapeutic entities. – Dr. Michael Hayden – 50 new products with...
– JPMorgan has downgraded Teva to “Underweight”, just two months after downgrading it to “Neutral.” – JPMorgan has downgraded Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; TASE: TEVA) to...
– Maalot S&P gives Israel Chemicals an AA+ rating with a “Negative” outlook after Uralkali announced that it was quitting its cartel. – Stefan Borgas...
– Analyst Gilad Alper: We will see Israel Chemicals’ share enter a long period of uncertainty. – / By Efrat Peretz / The new committee...